N4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, is pleased to announce the filing of its Patent Cooperation Treaty (“PCT”) patent application for the oral reformulation of Aprepitant (marketed by Merck & Co under the brand name Emend).
Aprepitant is an anti-emetic drug used to suppress nausea resulting from surgery and chemotherapy with global sales of over $500m last year and whose patent for the oral products expired in 2015.
Nigel Theobald, CEO of N4 Pharma, commented:
“This filing marks the next important step in the patent process for our Aprepitant application.
Sildenafil remains our lead project for generics and in line with our stated strategy, we will continue to progress our intellectual property for other possible generic reformulation opportunities that we can then develop at a later stage.”
